English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe August issue of The American Journal of Gastroenterology includes several articles on digital therapeutics and innovations in GI, encouraging adoption of emerging GI technologies to advance GI care.
Tag: ibs
New gut calming discovery to bring relief to IBS sufferers
The discovery of a strain of bacteria shown to reduce inflammation in the intestine caused by irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) could bring relief to millions of sufferers after being turned into an innovative natural food supplement by University of Bristol biotech spin-out Ferryx.
Histamine-producing gut bacteria can trigger chronic abdominal pain
The McMaster-Queen’s research team pinpointed the bacterium Klebsiella aerogenes as the key histamine producer by studying germ-free mice colonized with gut microbiota from patients with IBS. They also colonized some mice with gut microbiota from healthy volunteers as a control group.
The study found that the bacterium Klebsiella aerogenes converts dietary histidine, an essential amino acid present in animal and plant protein, into histamine, a known mediator of pain.
Smartphone App to Assess Stool Form, Rural-Urban Disparities in Cirrhosis Mortality, Lung Infection Risk in Severe Alcoholic Hepatitis in July Issue of AJG
The July issue of The American Journal of Gastroenterology highlights new clinical science including using a smartphone app to assess stool form, rural-urban disparities in cirrhosis mortality, and lung infection risk in severe alcohol-related hepatitis. This issue also includes articles on pediatric IBD, therapy options for Crohn’s disease, a novel endoscopic suturing device, proton pump inhibitors, and more.
Tipsheet: Cedars-Sinai Experts Share Research, Healthcare Innovations at Digestive Disease Week 2022
Cedars-Sinai physicians and scientists will share their latest advancements and research at Digestive Disease Week, known as DDW, an international scientific and clinical meeting featuring the work of physicians and researchers in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. DDW will take place May 21-24 in San Diego, California, and is available for virtual attendance.
November Issue of The American Journal of Gastroenterology Discusses Association Between BMI and Early-Onset Colorectal Cancer Risk, PPIs and All-Cause Mortality
The November issue of The American Journal of Gastroenterology features several articles examining the association between common conditions or treatments and the risk for disease development, including a study on the association between higher body mass index and increased risk for early-onset colorectal cancer, and a population study on proton pump inhibitors and all-cause mortality.
July Issue of The American Journal of Gastroenterology Includes Analysis of Psychological Comorbidities and Irritable Bowel Syndrome Prognosis
The July issue of AJG includes an examination of psychological comorbidities and the prognosis of individuals with IBS, as well as clinical research and reviews on cirrhosis, GERD, pediatrics, celiac disease, probiotics, GI quality improvement, NASH, and more.
Irritable Bowel Syndrome: Mark Pimentel, MD
Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder, affecting 10-15% of the world’s population. Approximately two-thirds of those who suffer from IBS are women. The disease can have mild forms or cause severe debilitation as diarrhea alternates with constipation. Severe cramping and bloating also are common. Because chronic IBS is so debilitating, it often disrupts the daily lives of people with this disorder.
Open-Label (Honest) Placebo Works as Well as Double-Blind Placebo in Irritable Bowel Syndrome
In a randomized clinical trial published in the journal PAIN, researchers found participants with moderate to severe irritable bowel syndrome (IBS) who were knowingly treated with a pharmacologically inactive pill — referred to as an honest or open-label placebo — reported clinically meaningful improvements in their IBS symptoms.
High-fat diet with antibiotic use linked to gut inflammation
UC Davis researchers have found that combining a Western-style high-fat diet with antibiotic use significantly increases the risk of developing pre- inflammatory bowel disease. This combination shuts down the mitochondria in cells of the colon lining, leading to gut inflammation. Mesalazine can help restart the mitochondria and treat pre-IBD condition.